Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
894 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03067181 | Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | recruiting | Phase 3 | 1,780 | Children's Oncology GroupNETWORK | 9 | Aug 25, 2026 | clinicaltrials |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments(MAGNETISMM-5) | recruiting | Phase 3 | 893 | PfizerINDUSTRY | 26 | Aug 24, 2026 |
| clinicaltrials |
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | recruiting | Phase 3 | 1,600 | Summit TherapeuticsINDUSTRY | 17 | Aug 24, 2026 | clinicaltrials |
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.(ADELA) | recruiting | Phase 3 | 300 | MedSIROTHER | 9 | Aug 24, 2026 | clinicaltrials |
| NCT05797168 | Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors(FONTANA) | recruiting | Phase 1 / Phase 2 | 602 | AstraZenecaINDUSTRY | 12 | Aug 21, 2026 | clinicaltrials |
| NCT06499285 | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | recruiting | Phase 3 | 225 | TakedaINDUSTRY | 26 | Aug 21, 2026 | clinicaltrials |
| NCT07209111 | A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)(KANDLELIT-014) | recruiting | Phase 2 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Aug 21, 2026 | clinicaltrials |
| NCT07687849 | Dietary Patterns Following a Firefighter Nutrition Education Programme(RESCUE) | recruiting | — | 350 | Avon Fire and Rescue ServiceOTHER_GOV | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05614739 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3(FORAGER-1) | recruiting | Phase 1 | 677 | Eli Lilly and CompanyINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | recruiting | Phase 3 | 1,300 | Kura Oncology, Inc.INDUSTRY | 16 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04495244 | A Study to Identify Breast Cancer (IDBC)(IDBC) | recruiting | — | 10,000 | Syantra Inc.INDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT05774951 | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy(CAMBRIA-1) | recruiting | Phase 3 | 4,300 | AstraZenecaINDUSTRY | 39 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06467357 | Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer(DESTINY-BTC01) | recruiting | Phase 3 | 620 | AstraZenecaINDUSTRY | 27 | Aug 19, 2026 | clinicaltrials |
| NCT06556563 | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma(EF-41) | recruiting | Phase 3 | 741 | NovoCure GmbHINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT06292780 | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)(LINKER-AL2) | recruiting | Phase 1 / Phase 2 | 220 | Regeneron PharmaceuticalsINDUSTRY | 6 | Aug 18, 2026 | clinicaltrials |
| NCT06743126 | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma(SUPRAME) | recruiting | Phase 3 | 360 | Immatics US, Inc.INDUSTRY | 6 | Aug 18, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT06792695 | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer(CANTOR) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 12 | Aug 18, 2026 | clinicaltrials |
| NCT06888388 | Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer(NSM) | recruiting | — | 4,700 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 8 | Aug 18, 2026 | clinicaltrials |
| NCT07033598 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia(PROSPERA) | recruiting | Phase 2 | 66 | TheradexINDUSTRY | 2 | Aug 18, 2026 | clinicaltrials |
| NCT05254743 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-314) | recruiting | Phase 3 | 737 | Loxo Oncology, Inc.INDUSTRY | 23 | Aug 17, 2026 | clinicaltrials |
| NCT05856370 | The Ailliance Post-Market Clinical Study | recruiting | N/A | 1,000 | Medtronic Spinal and BiologicsINDUSTRY | 6 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07665515 | Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(OVACT) | recruiting | Phase 1 | 50 | Epitopea LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer(RAMP 301) | recruiting | Phase 3 | 270 | Verastem, Inc.INDUSTRY | 16 | Aug 14, 2026 | clinicaltrials |
| NCT06149286 | A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma(OLYMPIA-5) | recruiting | Phase 3 | 580 | Regeneron PharmaceuticalsINDUSTRY | 18 | Aug 14, 2026 | clinicaltrials |
| NCT07313332 | Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation(ReHIIT_CON) | recruiting | N/A | 14 | University of NottinghamOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT(DURGA-5) | recruiting | Phase 3 | 750 | AstraZenecaINDUSTRY | 15 | Aug 14, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06980116 | Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 | 85 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT02300766 | Cerebellar Mutism Syndrome Study | recruiting | — | 2,000 | Rigshospitalet, DenmarkOTHER | 14 | Aug 12, 2026 | clinicaltrials |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | Phase 3 | 6,430 | Mats HeymanOTHER | 15 | Aug 12, 2026 | clinicaltrials |
| NCT05072314 | Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial(LOLIPOP) | recruiting | Phase 3 | 4,300 | Monash UniversityOTHER | 4 | Aug 12, 2026 | clinicaltrials |
| NCT05272709 | TT-702 in Patients With Advanced Solid Tumours.(CURATE) | recruiting | Phase 1 / Phase 2 | 60 | Cancer Research UKOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05417594 | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies(CERTIS1) | recruiting | Phase 1 / Phase 2 | 695 | AstraZenecaINDUSTRY | 7 | Aug 12, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT05391490 | Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies(KCAT19) | recruiting | Phase 1 | 12 | University College, LondonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05544526 | CAR T Cells to Target GD2 for DMG(CARMIGO) | recruiting | Phase 1 | 12 | University College, LondonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06731478 | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | recruiting | Phase 3 | 726 | Daiichi SankyoINDUSTRY | 26 | Aug 10, 2026 | clinicaltrials |
| NCT06926868 | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | recruiting | Phase 2 / Phase 3 | 600 | Bristol-Myers SquibbINDUSTRY | 28 | Aug 10, 2026 | clinicaltrials |
| NCT07336446 | A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs(ANDROMEDA) | recruiting | Phase 1 / Phase 2 | 300 | AstraZenecaINDUSTRY | 8 | Aug 10, 2026 | clinicaltrials |
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | recruiting | Phase 1 / Phase 2 | 350 | enGene, Inc.INDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT05809284 | Determining the Mechanisms of Loss of CAR T Cell Persistence(CARPERS) | recruiting | — | 50 | University College, LondonOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05999994 | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer(CAMPFIRE) | recruiting | Phase 2 | 105 | Eli Lilly and CompanyINDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT07751380 | Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma(MIGHTY) | recruiting | Phase 1 | 12 | University College, LondonOTHER | 1 | Aug 7, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials